Published: 3 June 2015
Author(s): P. Santus, D. Radovanovic, P. Paggiaro, A. Papi, A. Sanduzzi, N. Scichilone, F. Braido
Section: Review Article

Long-acting β2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.